NCT03517969: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 987 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03517969 |
|---|---|
| Title | A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 29, 2019 |
| Completion date | Aug. 10, 2021 |
| Required reporting date | Aug. 10, 2022, midnight |
| Actual reporting date | April 23, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 987 |